Publications by authors named "D G German"
Background: Research that investigates the negative health effects of stigma beyond the individual and interpersonal levels is increasingly using the concept of "structural stigma." This scoping review investigates how the concept of "structural stigma" has been used and operationalized in health-related literature to date in order to characterize its usage and inform future operationalizations.
Methods: A systematic search and screening process identified peer-reviewed, English-language research articles that used the term "structural stigma" available prior to January 1, 2024 in five databases (i.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests, or activities. Given the lack of specific pharmacological therapy for ASD and the clinical heterogeneity of the disorder, current biomarker research efforts are geared mainly toward identifying markers for determining ASD risk or for assisting with a diagnosis. A wide range of putative biological markers for ASD are currently being investigated.
View Article and Find Full Text PDFImportance: Safer supply programs were implemented in Canada to provide pharmaceutical-grade alternatives to the toxic unregulated drug supply. While research shows clinical benefits and reduced overdose mortality among safer supply patients, medication diversion remains a concern.
Objective: To examine provider (prescribing clinicians and allied health professionals) and patient perspectives on diversion of opioids prescribed in safer supply programs.
Background: Black cisgender women are disproportionately affected by HIV across the United States (US). Moreover, emerging adults continue to be significantly affected compared to women in older age groups. Yet in 2024, Black cisgender women and emerging adult women comprise a small fraction of HIV pre-exposure prophylaxis (PrEP) users in the US.
View Article and Find Full Text PDFArticle Synopsis
- Blood-based biomarkers are being studied to improve the detection and monitoring of Alzheimer's Disease in individuals with Down Syndrome, as current clinical diagnostics are challenging.
- Key biomarkers like phosphorylated tau (p-tau217, p-tau181) have shown strong connections to disease progression in Down Syndrome, suggesting they could be valuable in clinical settings.
- The research emphasizes the need for more understanding of biomarker variability, particularly regarding sex differences and the appropriate contexts for their clinical application in Alzheimer's diagnosis and treatment.